Need Help?

MASQ targeted amplicon sequencing data of AML samples at presentation, remission, and relapse, and MASQ data demonstrating performance ranges of the method.

MASQ targeted amplicon sequencing of AML blood or bone marrow at presentation, and relapse, when available, for 5 patients. Remission samples of both blood and bone marrow are included for 5 patients. Multiple batches (b1,b2) are used for 2 patients. There are 25 assays of AML data. MASQ data demonstrating sensitivity, input range, and batch size are also included, as 12 assays. All data is provided in paired FASTQ files.

Request Access

Data access committee for studies by the Wigler group

DATA ACCESS AGREEMENT These terms and conditions govern access to the managed access datasets (details of which are set out in Appendix I) to which the User Institution has requested access. The User Institution agrees to be bound by these terms and conditions. Definitions Authorised Personnel: The individuals at the User Institution to whom DAC for Wigler Group grants access to the Data. This includes the User, the individuals listed in Appendix II and any other individuals for whom the User Institution subsequently requests access to the Data. Details of the initial Authorised Personnel are set out in Appendix II. Data: The managed access datasets to which the User Institution has requested access. Data Producers: DAC for Wigler Group and the collaborators listed in Appendix I responsible for the development, organisation, and oversight of these Data. External Collaborator: A collaborator of the User, working for an institution other than the User Institution. Project: The project for which the User Institution has requested access to these Data. A description of the Project is set out in Appendix II. Publications: Includes, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. Research Participant: An individual whose data form part of these Data. Research Purposes: Shall mean research that is seeking to advance the understanding of genetics and genomics, including the treatment of disorders, and work on statistical methods that may be applied to such research. User: The principal investigator for the Project. User Institution(s): The Institution that has requested access to the Data. DAC for Wigler Group: The Data Access Committee for studies by the Wigler group at Cold Spring Harbor Laboratory. 1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf ) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf ). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify DAC for Wigler Group within 30 days of any changes or departures of Authorised Personnel. 13. The User Institution will notify DAC for Wigler Group prior to any significant changes to the protocol for the Project. 14. The User Institution will notify DAC for Wigler Group as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. DAC for Wigler Group may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than DAC for Wigler Group. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement. 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of England and Wales and shall be subject to the exclusive jurisdiction of the English courts.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001003732 Cancer Genomics

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00002529134 fastq.gz 5.6 GB
EGAF00002529135 fastq.gz 6.1 GB
EGAF00002529136 fastq.gz 21.6 GB
EGAF00002529137 fastq.gz 22.8 GB
EGAF00002529138 fastq.gz 518.9 MB
EGAF00002529139 fastq.gz 739.0 MB
EGAF00002529140 fastq.gz 544.3 MB
EGAF00002529141 fastq.gz 595.5 MB
EGAF00002529142 fastq.gz 12.8 GB
EGAF00002529143 fastq.gz 13.5 GB
EGAF00002529144 fastq.gz 9.3 GB
EGAF00002529145 fastq.gz 9.8 GB
EGAF00002529146 fastq.gz 199.7 MB
EGAF00002529147 fastq.gz 226.1 MB
EGAF00002529148 fastq.gz 519.6 MB
EGAF00002529149 fastq.gz 605.6 MB
EGAF00002529150 fastq.gz 10.9 GB
EGAF00002529151 fastq.gz 11.8 GB
EGAF00002529152 fastq.gz 10.7 GB
EGAF00002529153 fastq.gz 11.4 GB
EGAF00002529154 fastq.gz 700.8 MB
EGAF00002529155 fastq.gz 795.9 MB
EGAF00002529156 fastq.gz 22.7 GB
EGAF00002529157 fastq.gz 23.5 GB
EGAF00002529158 fastq.gz 2.7 GB
EGAF00002529159 fastq.gz 2.8 GB
EGAF00002529160 fastq.gz 466.0 MB
EGAF00002529161 fastq.gz 505.4 MB
EGAF00002529162 fastq.gz 4.2 GB
EGAF00002529163 fastq.gz 4.6 GB
EGAF00002529164 fastq.gz 5.8 GB
EGAF00002529165 fastq.gz 6.3 GB
EGAF00002529166 fastq.gz 463.1 MB
EGAF00002529167 fastq.gz 671.5 MB
EGAF00002529168 fastq.gz 420.0 MB
EGAF00002529169 fastq.gz 458.4 MB
EGAF00002529170 fastq.gz 11.3 GB
EGAF00002529171 fastq.gz 11.8 GB
EGAF00002529172 fastq.gz 8.6 GB
EGAF00002529173 fastq.gz 9.1 GB
EGAF00002529174 fastq.gz 214.4 MB
EGAF00002529175 fastq.gz 239.0 MB
EGAF00002529176 fastq.gz 428.0 MB
EGAF00002529177 fastq.gz 492.7 MB
EGAF00002529178 fastq.gz 10.7 GB
EGAF00002529179 fastq.gz 11.6 GB
EGAF00002529180 fastq.gz 11.8 GB
EGAF00002529181 fastq.gz 12.5 GB
EGAF00002529182 fastq.gz 21.0 GB
EGAF00002529183 fastq.gz 22.3 GB
EGAF00002529184 fastq.gz 2.9 GB
EGAF00002529185 fastq.gz 3.0 GB
EGAF00002529186 fastq.gz 22.4 GB
EGAF00002529187 fastq.gz 23.4 GB
EGAF00002529188 fastq.gz 53.0 MB
EGAF00002529189 fastq.gz 56.1 MB
EGAF00002529190 fastq.gz 3.3 GB
EGAF00002529191 fastq.gz 3.6 GB
EGAF00002529192 fastq.gz 100.2 MB
EGAF00002529193 fastq.gz 108.0 MB
EGAF00002529194 fastq.gz 192.3 MB
EGAF00002529195 fastq.gz 204.0 MB
EGAF00002529196 fastq.gz 265.4 MB
EGAF00002529197 fastq.gz 315.2 MB
EGAF00002529198 fastq.gz 18.7 GB
EGAF00002529199 fastq.gz 20.0 GB
EGAF00002530493 fastq.gz 25.5 GB
EGAF00002530494 fastq.gz 26.9 GB
EGAF00002530497 fastq.gz 23.7 GB
EGAF00002530498 fastq.gz 24.8 GB
EGAF00002530499 fastq.gz 957.6 MB
EGAF00002530500 fastq.gz 1.0 GB
EGAF00002530502 fastq.gz 21.0 GB
EGAF00002530503 fastq.gz 22.0 GB
74 Files (603.6 GB)